Biotechnology company exploiting protein splicing to develop next generation gene therapies
SpliceBio has raised €168M across 2 funding rounds from 9 investors, most recently a Series B round in Jun 2025. Based in Barcelona, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-06-11 | Series B | €118M | Asabys Partners,EQT Life Sciences,Gilde Healthcare,New Enterprise Associates,Novartis Venture Fund,Roche Venture Fund+3 more | View deal → |
| 2022-02-16 | Series A | €50M | Asabys Partners,Gilde Healthcare,New Enterprise Associates,Novartis Venture Fund,UCB Ventures,Ysios Capital | View deal → |
